ARIALYS THERAPEUTICS

arialys-therapeutics-logo

Arialys Therapeutics is a pre-clinical stage company that develops auto-antibody focusing on neuroscience. The company focuses on how the immune system impacts CNS health, disease, and treatment.

#SimilarOrganizations #People #Financial #Website #More

ARIALYS THERAPEUTICS

Social Links:

Industry:
Health Care Medical Therapeutics

Founded:
2022-01-01

Address:
La Jolla, California, United States

Country:
United States

Website Url:
http://www.arialysrx.com

Total Employee:
11+

Status:
Active

Total Funding:
58 M USD

Technology used in webpage:
CrUX Top 50m CrUX Dataset Vimeo


Similar Organizations

arcus-biosciences-logo

Arcus Biosciences

Arcus Biosciences is a biopharmaceutical company that discovers, develops, and commercializes novel therapies for the treatment of cancer.

cabaletta-bio-logo

Cabaletta Bio

Cabaletta Bio has adapted clinically-validated and FDA-approved CAR T cell technology to target B cell-mediated autoimmune diseases.

carisma-therapeutics-logo

Carisma Therapeutics

Carisma Therapeutics is a biotechnology company developing cellular immunotherapies to treat solid tumors.

intellia-therapeutics-logo

Intellia Therapeutics

Intellia Therapeutics is a genome editing company that develops curative gene-editing treatments.

mediar-therapeutics-logo

Mediar Therapeutics

Mediar is a preclinical stage biotechnology company developing therapeutics to halt, or even reverse, fibrosis.

polycore-therapeutics-logo

PolyCore Therapeutics

PolyCore Therapeuticsโ€™ team of life sciences scientists is dedicated to developing breakthrough treatments for CNS Diseases.

tango-therapeutics-logo

Tango Therapeutics

Tango Therapeutics is a biotechnology company that is developing next generation cancer therapies.

Current Employees Featured

mitsuyuki-matsumoto_image

Mitsuyuki Matsumoto
Mitsuyuki Matsumoto Scientific Founder and Chief Scientific Officer @ Arialys Therapeutics
Scientific Founder and Chief Scientific Officer
2022-07-01

Founder


mitsuyuki-matsumoto_image

Mitsuyuki Matsumoto

Investors List

mpm-capital_image

MPM Capital

MPM Capital investment in Seed Round - Arialys Therapeutics

johnson-johnson-innovation-jjdc_image

Johnson & Johnson Innovation โ€“ JJDC

Johnson & Johnson Innovation โ€“ JJDC investment in Seed Round - Arialys Therapeutics

avalon-bioventures_image

Avalon BioVentures

Avalon BioVentures investment in Seed Round - Arialys Therapeutics

catalys-pacific_image

Catalys Pacific

Catalys Pacific investment in Seed Round - Arialys Therapeutics

alexandria-venture-investments_image

Alexandria Venture Investments

Alexandria Venture Investments investment in Seed Round - Arialys Therapeutics

Official Site Inspections

http://www.arialysrx.com Semrush global rank: 6.09 M Semrush visits lastest month: 1.13 K

  • Host name: aacb0a264e514dd48.awsglobalaccelerator.com
  • IP address: 75.2.70.75
  • Location: Seattle United States
  • Latitude: 47.54
  • Longitude: -122.3032
  • Metro Code: 819
  • Timezone: America/Los_Angeles
  • Postal: 98108

Loading ...

More informations about "Arialys Therapeutics"

Arialys Therapeutics

Anti-NMDA receptor encephalitis (ANRE) is the most common form of autoimmune encephalitis. ANRE is a potentially lethal, poorly managed and often misdiagnosed neurological disease as โ€ฆSee details»

Team - arialysrx.com

Arialys Therapeutics is a private biotech company founded by Avalon BioVentures, Catalys Pacific, and MPM Capital. Our experienced internal team is focused on clinical evaluation of ART5803 while also partnering with our โ€ฆSee details»

Careers - arialysrx.com

At Arialys, we value diversity and are committed to providing equal employment opportunities. โ€ โ€Recruitment agencies may not submit CVs/resumes through the website and are prohibited from contacting our employees directly. We do not โ€ฆSee details»

Arialys - Catalys Pacific

Arialys Therapeutics, Inc. (โ€œArialysโ€), a private biotech company founded by Catalys Pacific along with Avalon BioVentures and MPM Capital, is exploring scientific breakthroughs in autoimmune mechanisms to develop new precision โ€ฆSee details»

Arialys Therapeutics - Crunchbase Company Profile

Arialys Therapeutics is a pre-clinical stage company that develops auto-antibody focusing on neuroscience. The company focuses on how the immune system impacts CNS health, disease, and treatment.See details»

Arialys Therapeutics, Inc. - Drug pipelines, Patents, Clinical trials ...

Nov 1, 2024 Arialys is headquartered in La Jolla, California. For more information, visit www.arialysrx.com . SOURCE: Arialys Therapeutics. ... The statistics for drugs in the Pipeline โ€ฆSee details»

Arialys Therapeutics, Inc. | LinkedIn

Arialys Therapeutics, Inc. Pharmaceutical Manufacturing La Jolla, California 2,082 followers Precision Medicines for Autoimmune Neuropsychiatric DiseasesSee details»

Arialys Therapeutics Company Profile 2024: Valuation, โ€ฆ

Arialys Therapeutics General Information Description. Developer of new precision medicines to specifically block pathogenic autoantibodies in the brain. The company specializes in the field of neuroscience and characterizes the nature โ€ฆSee details»

Arialys Therapeutics

Sep 12, 2023 Arialys is headquartered in the Avalon BioVentures Accelerator on the Torrey Pines Mesa, in La Jolla, California. For more info, visit www.arialysrx.com. Contacts. โ€ฆSee details»

Arialys Therapeutics Appoints Peter Flynn, Ph.D., President

Jun 25, 2024 LA JOLLA, Calif.--(BUSINESS WIRE)-- Arialys Therapeutics, a biotechnology company pioneering new precision medicines for autoimmune neuropsychiatry, today โ€ฆSee details»

Arialys Therapeutics Appoints Peter Flynn, Ph.D., President and โ€ฆ

LA JOLLA, Calif., June 25, 2024--Arialys Therapeutics, a biotechnology company pioneering new precision medicines for autoimmune neuropsychiatry, today announced the appointment of โ€ฆSee details»

Arialys Therapeutics Launches to Lead the Development of New โ€ฆ

Sep 12, 2023 LA JOLLA, Calif.--(BUSINESS WIRE)-- Arialys Therapeutics, a biotechnology company pioneering new therapeutics for autoimmune neuropsychiatry, today announced the โ€ฆSee details»

Arialys Therapeutics Raises $58M to Target Autoimmune โ€ฆ

Sep 19, 2023 Jay Lichter, PhD President and CEO Arialys Therapeutics. Arialys Therapeutics is seeking to make its mark on the neurological market by developing treatments for autoimmune โ€ฆSee details»

Arialys Therapeutics Announces First Participants Dosed in a Phase โ€ฆ

โ€ข ART5803 is being developed for the treatment of anti-NMDAR autoimmune neuropsychiatric diseases, including anti-NMDAR encephalitis (ANRE) โ€ข Preclinical data in higher animal โ€ฆSee details»

Arialys Therapeutics

LA JOLLA, Calif., June 25, 2024 โ€“ Arialys Therapeutics, a biotechnology company pioneering new precision medicines for autoimmune neuropsychiatry, today announced the appointment of โ€ฆSee details»

Arialys Therapeutics Launches to Lead the Development of New โ€ฆ

LA JOLLA, Calif., September 12, 2023--Arialys Therapeutics Launches to Lead the Development of New Precision Medicines for Autoimmune Neuropsychiatric DiseasesSee details»

Arialys Therapeutics Launches to Lead the Development of New โ€ฆ

Sep 12, 2023 Arialys is headquartered in the Avalon BioVentures Accelerator on the Torrey Pines Mesa, in La Jolla, California. For more info, visit www.arialysrx.com. Contacts. โ€ฆSee details»

News & Events - arialysrx.com

Arialys Therapeutics News & Events. Arialys Therapeutics Announces First Participants Dosed in a Phase 1 Clinical Trial of ART5803, a Precision Medicine for the Treatment of Autoimmune โ€ฆSee details»

Arialys Therapeutics Launches to Lead the Development of New โ€ฆ

Sep 12, 2023 Arialys was founded on the breakthrough understanding that immune cells โ€“ not only in the bodyโ€™s periphery but especially in the brain โ€“ can produce autoantibodies that โ€ฆSee details»

Arialys Therapeutics Launches to Lead the Development of New โ€ฆ

Sep 12, 2023 LA JOLLA, Calif.--(BUSINESS WIRE)--Arialys Therapeutics, a biotechnology company pioneering new therapeutics for autoimmune neuropsychiatry, today announced the โ€ฆSee details»

linkstock.net © 2022. All rights reserved